Autoraccolta di campioni cervicali per il test HPV per migliorare la sperimentazione SHIP (Prevenzione del cancro cervicale). (SHIP-A-S01)
Iniziativa "Last Mile" del cancro cervicale dell'NCI "Self-Collection for HPV Testing to Improve Cervical Cancer Prevention" (SHIP) Studio LMI-001-A-S01
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not undergo screening that involves pelvic exams. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. Without appropriate screening and care, preventable pre-cancers may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own vaginal sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. This study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician.
The Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and/or post-approval regulatory requirements.
Panoramica dello studio
Stato
Intervento / Trattamento
- Altro: Questionnaire Administration
- Altro: Survey Administration
- Altro: Electronic Health Record Review
- Procedura: Biospecimen Collection
- Procedura: Cervical Biopsy
- Procedura: Colposcopy
- Procedura: Endocervical Curettage
- Procedura: Excision
- Procedura: HPV Self-Collection
- Procedura: Human Papillomavirus Test
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate clinical accuracy (including clinical sensitivity, clinical specificity, false positive rate, and false negative rate) for the detection of cervical precancer/cancer and agreement/concordance (including positive percent agreement and negative percent agreement) on self-collected (SC) versus clinician collected (CC) samples for the following HPV genotype detections and groupings by Becton, Dickinson and Company (BD) Onclarity (trademark) HPV assay: Any high risk (HR) HPV genotype, HPV16, HPV18, HPV31, HPV45, HPV51, HPV52, HPV33/58, HPV35/39/68, HPV56/59/66, HPV16 and/or HPV18, other 12 HR-HPV types (grouped). (Group A) II. To conduct an observational study among women attending regular cervical cancer screening ("intended use population" for the at-home collection indication). (Group B)
EXPLORATORY OBJECTIVES:
I. To evaluate human factors affecting usability, acceptability, and preferences for self-collection. (Group A) II. To evaluate agreement/concordance (including positive percent agreement and negative percent agreement) on SC versus CC samples for the following HPV genotype detections and groupings by BD Onclarity™ HPV assay: Any HR HPV genotype, HPV16, HPV18, HPV31, HPV45, HPV51, HPV52, HPV33/58, HPV35/39/68, HPV56/59/66, HPV16 and/or HPV18, other 12 HR-HPV types (grouped). (Group B) III. To evaluate human factors affecting usability, acceptability, and preferences for self-collection. (Group B)
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP A: Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
GROUP B: Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of 1 or 2 cervical test samples. Patients may undergo standard of care colposcopy with biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
After completion of study intervention (one time), laboratory results available within 30 days are collected for study analysis purposes.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
San Juan, Porto Rico, 00936
- University of Puerto Rico
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- Louisiana State University Health Science Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
-
New York
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Einstein Campus
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- UPMC-Magee Womens Hospital
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- GROUP A: Willingness and ability to provide a documented informed consent
- GROUP A: Is 25 years or older
- GROUP A: Has an intact cervix
- GROUP A: Has had a referral for colposcopy or cervical excisional procedure in which routine cervical cancer screening has included positive HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance [ASC-US] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit
- GROUP A: Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable
- GROUP B: Willingness and ability to provide a documented informed consent
- GROUP B: Is 25 years or older
- GROUP B: Has an intact cervix
- GROUP B: Eligible for regular cervical cancer screening by current national guidelines
Exclusion Criteria:
- GROUP A: Is pregnant when presenting for the referral visit or gave birth within the past 3 months
- GROUP A: Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure [LEEP], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit
- GROUP A: Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records
- GROUP A: Known medical conditions that, in the opinion of the investigator, preclude study participation
- GROUP A: Previous participation in the SHIP trial (participation is defined as completing the self-collection sampling) or another cervical cancer screening study that involved vaginal sampling within the past 12 months
- GROUP A: Is experiencing unusual bleeding or pelvic pain
- GROUP B: Is known to be pregnant when presenting for the screening visit or gave birth within the past 3 months
- GROUP B: Has a known history of excisional or ablative therapy to the cervix (e.g., LEEP, cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the screening visit
- GROUP B: Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records
- GROUP B: Known medical conditions that, in the opinion of the investigator, preclude study participation
- GROUP B: Previous participation in the SHIP Trial (participation is defined as completing the self-collection sampling) or another cervical cancer screening study that involved vaginal sampling within the past 12 months
- GROUP B: Is experiencing any bleeding (including menstruation) or pelvic pain
- GROUP B: Is experiencing any active vaginal infection or has used any vaginal products in 48 hours previous to study sample collection
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group A (self-collected and clinician-collected samples)
Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated. |
Ancillary studies Ancillary studies Ancillary studies Undergo collection of cervical samples by clinician
Altri nomi:
Undergo cervical biopsy conducted by clinician Undergo colposcopy conducted by clinician
Altri nomi:
Undergo endocervical curettage conducted by clinician Undergo cervical excisional procedure conducted by clinician
Altri nomi:
Undertake self-collection of vaginal samples
Altri nomi:
Undergo HPV testing of self-collected vaginal samples and cervical samples
Altri nomi:
|
|
Sperimentale: Group B (self-collected and clinician-collected samples)
Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of 1 or 2 cervical test samples. Patients may undergo standard of care colposcopy with biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated. |
Ancillary studies Ancillary studies Ancillary studies Undergo collection of cervical samples by clinician
Altri nomi:
Undergo cervical biopsy conducted by clinician Undergo colposcopy conducted by clinician
Altri nomi:
Undergo endocervical curettage conducted by clinician Undergo cervical excisional procedure conducted by clinician
Altri nomi:
Undertake self-collection of vaginal samples
Altri nomi:
Undergo HPV testing of self-collected vaginal samples and cervical samples
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical sensitivity for self-collected (SC) samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing human papillomavirus (HPV) positive on SC sample given disease positive (e.g., cervical intraepithelial neoplasia [CIN]2+). Will report point estimate and 95% confidence intervals (CIs). |
One-time, up to 30 days
|
|
Clinical sensitivity for clinician-collected (CC) samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV positive on CC sample given disease positive (e.g., CIN2+). Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Sensitivity ratio for SC versus CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the sensitivity of SC divided by the sensitivity of CC. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Difference in clinical sensitivity between SC and CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Clinical specificity for SC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV negative on SC sample given disease negative (e.g., < CIN2). Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Clinical specificity for CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV negative on CC sample given disease negative (e.g., < CIN2). Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Specificity ratio for SC versus CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the specificity of SC divided by the specificity of CC. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Difference in clinical specificity between SC and CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
False positive rate (FPR) for SC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV positive on SC sample given < CIN2. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
FPR for CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV positive on CC sample given < CIN2. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
FPR ratio for SC versus CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
The FPR ratio is the FPR of SC divided by the FP of CC. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Difference in FPR ratio between SC and CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
False negative rate (FNR) for SC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV negative on SC given CIN2+. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
FNR for CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of testing HPV negative on CC given CIN2+. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
FNR ratio for SC versus CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
The FNR ratio is the FNR of SC divided by the FNR of CC. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Difference in FNR ratio between SC and CC samples (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Positive percent agreement (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of positive on SC given positive on CC, expressed as a percent. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Negative percent agreement (Group A)
Lasso di tempo: One-time, up to 30 days
|
Will be defined as the probability of negative on SC given negative on CC, expressed as a percent. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Positive percent agreement (Group A and Group B)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Negative percent agreement (Group A and Group B)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Cohen's Kappa (Group A and Group B)
Lasso di tempo: One-time, up to 30 days
|
Will be described as a measure of agreement beyond chance between SC and CC samples, and values will be interpreted as follows: 0.00-0.19 as poor, 0.20-0.39 as fair, 0.40-0.59 as moderate, 0.60-0.79 as good, and 0.80-1.00 as excellent agreement beyond chance. Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Test positivity rates (Group A and Group B)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
|
Rate of invalid test results (Group A and Group B)
Lasso di tempo: One-time, up to 30 days
|
Will report point estimate and 95% CIs. |
One-time, up to 30 days
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Human factors affecting usability
Lasso di tempo: One-time, up to 30 days
|
Will be assessed by questionnaire data. |
One-time, up to 30 days
|
|
Human factors affecting acceptability
Lasso di tempo: One-time, up to 30 days
|
Will be assessed by questionnaire data. |
One-time, up to 30 days
|
|
Human factors affecting references for self-collection
Lasso di tempo: One-time, up to 30 days
|
Will be assessed by questionnaire data. |
One-time, up to 30 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Vikrant V Sahasrabuddhe, National Cancer Institute Division of Cancer Prevention
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Attributi della malattia
- Infezioni
- Malattie virali
- Malattie uterine
- Malattie genitali, femmina
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da virus del DNA
- Neoplasie genitali, femmina
- Malattie della cervice uterina
- Neoplasie uterine
- Infezioni da virus tumorali
- Condizioni patologiche, segni e sintomi
- Neoplasie cervicali uterine
- Infezioni da papillomavirus
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Procedure chirurgiche minimamente invasive
- Tecniche diagnostiche, chirurgiche
- Endoscopia
- Procedure chirurgiche urogenitali
- Tecniche genetiche
- Procedure chirurgiche ginecologiche
- Procedure chirurgiche ostetriche
- Tecniche diagnostiche, ostetriche e ginecologiche
- Tecniche diagnostiche molecolari
- Gestione dei campioni
- Colposcopia
- Test del DNA del papillomavirus umano
Altri numeri di identificazione dello studio
- NCI-2024-05879
- NCI-2024-05879 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- LMI-001-A-S01 (Altro identificatore: DCP)
- LMI-001-A-S01 (Altro identificatore: National Cancer Institute Division of Cancer Prevention)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .